Eliquis®
Apixaban
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$600
With Insurance
$50-100
The Short Version
Evidence summary
Eliquis (Apixaban) is a Direct Oral Anticoagulant (DOAC / Factor Xa Inhibitor) prescribed for Atrial fibrillation (stroke prevention) and Deep vein thrombosis (DVT) treatment. FDA-approved in 2012.
Apixaban reaches peak blood levels within 3-4 hours — anticoagulation begins almost immediately after the first dose.
The most commonly reported side effects are Bruising (ecchymosis) (10%), Minor bleeding (nosebleeds, gum bleeding) (5-10%), Nausea (3%). Expected effect of blood thinning; avoid trauma when possible
Review the funding details in the evidence section below.
What This Really Costs
Long-term cost projection based on current pricing
Monthly
$575
$75 w/ insurance
without insurance
Annual
$6.9K
$900 w/ insurance
without insurance
10 Years
$69K
$9K w/ insurance
without insurance
30 Years
$207K
$27K w/ insurance
without insurance
Lifestyle alternative: $0/month in prescriptions. Weight loss (for AFib) — LEGACY trial: 10% weight loss associated with 6x greater probability of AFib-free survival.
The average American retiree spends $165,000 on healthcare over their lifetime (Fidelity, 2024). Informed choices today compound over decades.
Quick Answers
Now what?
You've read the evidence. Here are your next steps.
Related Evidence
Explore related medications reviewed on EvidentMeds
FDA Black Box Warning
SPINAL/EPIDURAL HEMATOMA & PREMATURE DISCONTINUATION
Epidural or spinal hematomas may occur in patients treated with Eliquis who are receiving neuraxial anesthesia or undergoing spinal puncture — can result in permanent paralysis. Premature discontinuation increases the risk of thrombotic events including stroke.
Strict Contraindications
How It Works
Apixaban directly inhibits Factor Xa, a key enzyme in the coagulation cascade. By blocking Factor Xa, apixaban prevents the conversion of prothrombin to thrombin — effectively slowing the entire clotting process without eliminating it. This reduces the risk of blood clots (stroke, DVT, PE) while maintaining some ability to clot.
Why the side effects happen
Bleeding is the primary risk because the same mechanism that prevents pathological clots also impairs normal hemostasis. Bruising and minor bleeding are common. The lack of a routine monitoring test (unlike warfarin's INR) means over-anticoagulation can go undetected.
When Will I Feel It?
Apixaban reaches peak blood levels within 3-4 hours — anticoagulation begins almost immediately after the first dose.
Peak blood levels reached. Anticoagulation effect begins within 1-2 hours and peaks at 3-4 hours.
Consistent anticoagulation achieved with twice-daily dosing. Half-life is ~12 hours.
Adherence Note
Twice-daily dosing is required because apixaban has a 12-hour half-life. Missing doses creates gaps in protection that increase stroke risk.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Understanding Anticoagulation — Limited Lifestyle Alternatives
Unlike blood pressure or cholesterol, atrial fibrillation and blood clot disorders generally require medication. There is no lifestyle intervention that replaces anticoagulation for stroke prevention in AFib. However, addressing root causes of AFib may reduce the need for long-term anticoagulation.
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Weight loss (for AFib)
Obesity is a major independent risk factor for atrial fibrillation. Weight loss can reduce AFib burden and, in some cases, restore normal rhythm — potentially eliminating the need for anticoagulation.
LEGACY trial: 10% weight loss associated with 6x greater probability of AFib-free survival
Alcohol reduction
Alcohol is a well-established trigger for atrial fibrillation. Even moderate drinking increases AFib risk.
Abstinence from alcohol reduced AFib recurrence by 37% in the ARREST-AF cohort
Exercise (moderate)
Regular moderate exercise reduces AFib risk and recurrence. However, extreme endurance exercise (ultramarathons, professional cycling) may increase AFib risk.
Moderate exercise associated with 10-15% reduction in AFib incidence
Sleep apnea treatment
Untreated obstructive sleep apnea doubles AFib risk. CPAP treatment reduces recurrence after cardioversion or ablation.
CPAP treatment associated with 42% reduction in AFib recurrence
How It Compares
Apixaban (Eliquis) has the best overall safety profile among DOACs — lowest rates of major bleeding in head-to-head comparisons with warfarin and other DOACs.
Strengths
- Lowest major bleeding rate among DOACs
- No dietary restrictions (unlike warfarin — no vitamin K monitoring)
- No routine blood monitoring required
- Predictable pharmacokinetics
- Twice-daily dosing provides more consistent anticoagulation
Weaknesses
- Very expensive ($550-600/month in US — no generic until ~2028)
- No widely available reversal agent for emergencies (andexanet alfa exists but costs ~$50,000 per dose)
- No routine monitoring test — harder to detect over-anticoagulation
Clinically Preferred Alternatives
Global Prescribing & Pricing
Eliquis is the most prescribed anticoagulant worldwide; pricing varies dramatically between countries
United States
$550-600/mo
#1 prescribed anticoagulant; massive direct-to-consumer advertising
No price negotiation until 2026 (Inflation Reduction Act); one of the most advertised drugs in US
Usually covered with high copay
United Kingdom
~$50-70/mo
NICE-approved for AFib stroke prevention
NHS negotiated pricing — 10x cheaper than US
Covered by NHS
France
~$60-80/mo
Widely prescribed; preferred over warfarin
Government reference pricing
Covered by Sécurité Sociale
Germany
~$80-100/mo
Standard of care for new AFib diagnoses
Reference pricing with benefit assessment
Covered by GKV
Japan
~$100-140/mo
Increasingly used; replacing warfarin
National formulary pricing
Covered by JHIS
Eliquis costs $550-600/month in the US and $50-70 in the UK — an 8-10x difference. It is one of the highest-revenue drugs in pharmaceutical history ($20B+ annually). The Inflation Reduction Act will allow Medicare to negotiate its price starting in 2026, which may change the landscape significantly.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
ARISTOTLE: Funded by Bristol-Myers Squibb and Pfizer — the companies that manufacture and co-market Eliquis. The trial compared Eliquis to warfarin and was designed, analyzed, and interpreted with sponsor involvement. AVERROES: Also funded by BMS/Pfizer. AMPLIFY: Also funded by BMS/Pfizer.
Declared Conflicts of Interest
All three pivotal trials were funded by the manufacturer. Lead investigators received research grants, consulting fees, and/or speaker honoraria from BMS and Pfizer. The sponsor had roles in study design, data collection, data analysis, and manuscript preparation. Independent replication of results has not been performed at the same scale.
Key Efficacy Results
ARISTOTLE: 21% reduction in stroke vs warfarin, 31% less major bleeding; AVERROES: Superior to aspirin in patients intolerant of warfarin
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Apixaban. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Apixaban in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| ARISTOTLE (BMS/Pfizer) | NCT00412984 | |
| AVERROES (BMS/Pfizer) | NCT00496769 | |
| AMPLIFY (BMS/Pfizer) | NCT00643201 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Bruising (ecchymosis)
10%Expected effect of blood thinning; avoid trauma when possible
Minor bleeding (nosebleeds, gum bleeding)
5-10%Usually manageable; apply pressure. Report if persistent.
Nausea
3%Take with food; usually transient
Anemia
3%Monitor hemoglobin; may indicate occult bleeding
Fatigue
2%If new, check hemoglobin — may indicate blood loss
Serious Adverse Effects
- • Major gastrointestinal bleeding — 0.8% per year
- • Intracranial hemorrhage — 0.3% per year
- • Spinal/epidural hematoma (with neuraxial procedures)
- • Life-threatening bleeding requiring transfusion
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Major gastrointestinal bleeding — 0.8% per year
- Intracranial hemorrhage — 0.3% per year
- Spinal/epidural hematoma (with neuraxial procedures)
- Life-threatening bleeding requiring transfusion
- New onset of any neurological symptoms (stroke signs: face drooping, arm weakness, speech difficulty)
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
No adequate studies. Presumed risk of maternal and fetal hemorrhage. Use heparin alternatives in pregnancy.
Unknown if excreted in human milk. Risk of infant bleeding.
Estrogen decline is associated with increased atrial fibrillation risk, which is the primary reason Eliquis is prescribed. Women are often diagnosed with AFib later than men and may be underanticoagulated. Ensure your stroke risk has been properly assessed.
Safety and efficacy not established in children under 18.
Reduce to 2.5mg twice daily if age ≥80 AND (weight ≤60kg OR creatinine ≥1.5). Bleeding risk increases with age.
Reduce dose in severe renal impairment (CrCl 15-29). Avoid if CrCl <15 or on dialysis.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Stopping Eliquis without medical supervision increases the risk of stroke (in AFib patients) or recurrent blood clots (in DVT/PE patients). There is no taper — it is either on or off. The decision to stop must involve assessing ongoing clot risk.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Eliquis does not require tapering — it is stopped rather than tapered
- ·The decision to discontinue must be made with your doctor based on ongoing stroke/clot risk assessment
- ·If stopping for surgery, specific timing guidelines exist (typically 48 hours before procedure for normal kidney function)
- ·Bridging with heparin may be needed in high-risk patients during perioperative periods
Warning Symptoms — Contact Your Doctor If You Experience:
- New onset of any neurological symptoms (stroke signs: face drooping, arm weakness, speech difficulty)
- Leg swelling or pain (DVT signs)
- Shortness of breath (PE signs)
- Any unusual bleeding after stopping
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.What is my actual stroke risk score (CHA₂DS₂-VASc)?
- 2.Could weight loss or alcohol reduction eliminate my AFib?
- 3.What happens if I miss a dose?
- 4.When can I safely stop taking this — or is it lifelong?
- 5.What do I do before dental work or surgery?
Lab Tests to Request
- CBC (hemoglobin/hematocrit) at baseline and periodically
- Kidney function (creatinine/GFR)
- Liver function
- CHA₂DS₂-VASc score assessment
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Eliquis®
- What is Eliquis® used for?
- Eliquis® (Apixaban) is a Direct Oral Anticoagulant (DOAC / Factor Xa Inhibitor) manufactured by Bristol-Myers Squibb / Pfizer. FDA-approved indications include: Atrial fibrillation (stroke prevention); Deep vein thrombosis (DVT) treatment; Pulmonary embolism (PE) treatment; DVT/PE prevention after hip or knee replacement.
- What are the common side effects of Eliquis®?
- Common side effects of Eliquis® include: Bruising (ecchymosis) (10%); Minor bleeding (nosebleeds, gum bleeding) (5-10%); Nausea (3%); Anemia (3%); Fatigue (2%).
- How much does Eliquis® cost?
- Eliquis® list price is approximately $600. With insurance it typically costs $50-100; without insurance approximately $550-600.
- Who funded the clinical trials for Eliquis®?
- ARISTOTLE: Funded by Bristol-Myers Squibb and Pfizer — the companies that manufacture and co-market Eliquis. The trial compared Eliquis to warfarin and was designed, analyzed, and interpreted with sponsor involvement. AVERROES: Also funded by BMS/Pfizer. AMPLIFY: Also funded by BMS/Pfizer.
- How strong is the clinical evidence for Eliquis®?
- Key studies: ARISTOTLE, AVERROES, AMPLIFY. ARISTOTLE: 21% reduction in stroke vs warfarin, 31% less major bleeding; AVERROES: Superior to aspirin in patients intolerant of warfarin Potential conflicts of interest: All three pivotal trials were funded by the manufacturer. Lead investigators received research grants, consulting fees, and/or speaker honoraria from BMS and Pfizer. The sponsor had roles in study des.
- Are there non-drug alternatives to Eliquis®?
- Unlike blood pressure or cholesterol, atrial fibrillation and blood clot disorders generally require medication. There is no lifestyle intervention that replaces anticoagulation for stroke prevention in AFib. However, addressing root causes of AFib may reduce the need for long-term anticoagulation. See the Alternatives tab for full details.
Get notified when we update Eliquis®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.